Newsroom

"We need heroes to help dying patients."…
Could 100 Be the New 60?
Fighting Age-Related Muscle Loss
Astronaut Buzz Aldrin Relies on Re Muscl…
Dr. Robert J. Hariri Chairman of MYOS Co…
The Government’s Bad Diet Advice
Raw Eggs and No Husband Since ’38 Keep…
Chairman Dr. Robert Hariri of MYOS Corpo…
US egg consumption grows for a fifth con…
Huff Post conversation with MYOS Chairma…
Founder and Chairman of MYOS Corporation…
Equities.com Interviews MYOS Chief Medic…
Eat to Beat Sarcopenia: Foods That Won't…
White Paper: The Effect of Fortetropin o…
BioWorld: “In The Clinic” Spotlights…
MYOS Reports Positive Top-Line Clinical …
BioWorld: “Myos, Cloud collaborate to …
“Contact Light” - A Tribute To MYOS …
Biotech Visionaries Venter, Hariri and D…
Scientific American worldVIEW Includes M…
MYOS Chairman Robert Hariri to speak at …
Why MYOS? One-on-One With MYOS General C…
Letterman's Doctor and MYOS Board Member…
Optimal Wellness Radio Hour Featuring MY…
Why MYOS? One-on-One With Maghsoud Daria…
MYOS Corporation Featured in Muscle & Fi…
MYOS Corporation to Present at the Third…
Why MYOS? One-on-One With CMO Dr. Robert…
The Courage to Change the World
The Life Sciences Report Interview With …
MYOS Corp. announces appointment of DosS…
Why MYOS? One-on-One With President and …
"Drugs Aim to Help Elderly Rebuild Muscl…
Sarcopenia and the FDA: A Time for Chan…
Diamandis Named 50 Greatest Leaders
Follow MYOS on Social Media!
26
September

Equities.com Interviews MYOS Chief Medical Officer Dr. Robert Ashton

MYOS Corporation was a presenting company at the recent Aegis Capital Corp. 2014 Healthcare & Technology Conference, held earlier this month in Las Vegas, Nevada. While at the conference, MYOS Chief Medical Officer Dr. Robert Ashton was interviewed by Joel Anderson of Equities.com to discuss the work MYOS is doing in BioNutrition and BioTherapeutics. “We are already developing

13
August

Eat to Beat Sarcopenia: Foods That Won’t “Frail” You

Written by Dr. Robert Ashton, MYOS Chief Medical OfficerOriginally published by Third Age on August 12, 2014With aging comes frailty. The more frail we are, the more likely we are to get sick or die from chronic illnesses including heart disease, diabetes, and other leading causes of death. If you can slow the debilitating process, then you have a shot at living not only a longer life,

06
August

White Paper: The Effect of Fortetropin™ on Muscle

Clinical effects on lean body mass, fat mass and muscle size; Implications for use and proposed mechanism of action.  View the whitepaper with the study results INTRODUCTION Muscle tissue is increasingly recognized as a key marker for overall health and wellness. The preservation of muscle mass and muscle quality is considered central to the management of the symptoms of aging and many

23
July

BioWorld: “In The Clinic” Spotlights MYOS Fortetropin™ Clinical Trial

Originally published in BioWorld™ Today, Volume 25, No. 138 Myos Corp., of Cedar Knolls, N.J., reported positive top-line results of its trial designed to study the effects of Fortetropin (MYO-T12) in conjunction with modest resistance training in male subjects. The trial was designed to analyze important body composition measurements and strength performance at two dose levels of

22
July

MYOS Reports Positive Top-Line Clinical Study Results of Foretropin™, Led by Jacob Wilson, Ph.D. CSCS*D at the University of Tampa

In April 2014, we announced a clinical study of Fortetropin™ on resistance-trained males, led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory of the Department of Health Sciences and Human Performance at The University of Tampa. After evaluating 45 male subjects adhering to a supervised nutritional intake program and a

18
July

BioWorld: “Myos, Cloud collaborate to 'muscle in' on new therapeutic category”

Originally published in BioWorld™ Today, Volume 25, No. 138Written by Marie Powers, BioWorld Staff Writer Myos Corp., which is taking a bifurcated approach in developing products to improve muscle mass, increase mobility and reduce frailty, is going to the "cloud" through a research and development agreement with newco Cloud Pharmaceuticals Inc. Although terms were not disclosed, the

17
July

“Contact Light” - A Tribute To MYOS Board Member, Dr. Buzz Aldrin

"Contact light." Those were the first words uttered by a human after Apollo 11 landed on the moon. It was 45 years ago today that Apollo 11 started it's journey to the moon and back. Buzz Aldrin was the lunar module pilot who made that statement. "Contact light" referred to a light inside the Apollo 11 landing module (The Eagle) that flickered as a probe at the bottom of the spacecraft touched

14
July

Biotech Visionaries Venter, Hariri and Diamandis Unite on MYOS Board of Directors

MYOS Corporation announced today that it has appointed genomic pioneer, J. Craig Venter, Ph.D. to its Board of Directors. The “three musketeers of innovation,” J. Craig Venter, Ph.D., Robert J. Hariri, M.D., Ph.D. and Peter Diamandis, M.D. have united prior to MYOS as co-founders of Human Longevity, Inc., a genomics and cell therapy-based diagnostic and therapeutic company. Now,

26
June

Scientific American worldVIEW Includes MYOS Sponsor Feature “Staying Strong"

We are excited to sponsor the 2014 edition of Scientific American worldVIEW: A Global Biotechnology Perspective, which was unveiled this week at the 2014 BIO International Conference in San Diego, California. Sarcopenia and the importance of muscle health are the key topics in the MYOS Corporation sponsor feature, "Staying Strong," included on pages 8-9 of the issue and also available online

26
June

MYOS Chairman Robert Hariri to speak at 2014 BIO Convention During Scientific American Super Session

MYOS Chairman Dr. Robert Hariri will be speaking during the Scientific American WorldView Super Session—Biotech: We are the World-today—at the BIO International Convention in San Diego, California. This event will explore key themes from Scientific American's annual biotechnology edition, featuring the worldVIEW Scorecard and fresh perspectives on international life science